Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is one of the largest biopharmaceutical companies globally, headquartered in North Chicago, Illinois. The company specializes in immunology, oncology, neuroscience, aesthetics, and eye care therapeutics, making its news coverage particularly valuable for tracking developments across multiple billion-dollar healthcare markets.
AbbVie news reflects the company diverse therapeutic focus. Immunology updates often include clinical trial results for next-generation autoimmune disease treatments, including JAK inhibitors and other novel mechanisms targeting conditions like rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. These announcements can signal shifts in competitive dynamics within the autoimmune drug market.
The oncology division generates news around FDA approvals, clinical trial data, and pipeline developments for cancer therapies. AbbVie cancer portfolio includes treatments for hematologic malignancies such as chronic lymphocytic leukemia and multiple myeloma, with ongoing expansion into solid tumor indications. Drug approval timelines and efficacy data from late-stage trials represent key news catalysts.
Neuroscience news covers developments in migraine treatment and Parkinson disease therapies, including CGRP-targeting drugs and advanced delivery systems. The Allergan Aesthetics division, acquired through AbbVie purchase of Allergan, generates news around cosmetic treatment innovations, market expansion, and competitive positioning in the medical aesthetics space.
Quarterly earnings reports provide insight into segment performance across immunology, oncology, and aesthetics divisions. Strategic announcements regarding acquisitions, licensing deals, and pipeline partnerships appear regularly as AbbVie pursues external innovation to supplement internal research. Bookmark this page to track regulatory decisions, clinical milestones, and strategic moves from one of biopharma largest players.
The European Commission has approved RINVOQ (upadacitinib) for adults with moderately to severely active ulcerative colitis, marking its fifth indication in the EU. This decision is supported by three Phase 3 studies demonstrating significant clinical remission, response, and mucosal healing at weeks 8 and 52. Specifically, 26-33% of patients achieved clinical remission at week 8 during induction, and 42-52% at week 52 during maintenance, compared to 4-12% for placebo. Safety results were consistent with prior data, with no new significant risks identified.
AbbVie and Allergan Aesthetics will present over 30 abstracts at the TOXINS 2022 Conference from July 27-30 in New Orleans. Key topics include clinical studies on onabotulinumtoxinA (BOTOX) for chronic migraine, cervical dystonia, and aesthetic applications. Noteworthy presentations include findings from the CD-PROBE study analyzing onabotulinumtoxinA's safety and efficacy in cervical dystonia. AbbVie emphasizes its ongoing commitment to neurotoxin research and enhancing patient outcomes through medical education, showcasing advancements in both therapeutic and aesthetic domains.
AbbVie has announced a strategic alliance with iSTAR Medical to develop and commercialize the MINIject® device, a minimally invasive glaucoma surgical device. This partnership aims to enhance AbbVie's eye care portfolio and improve treatment options for glaucoma patients. The agreement includes a $60M upfront payment to iSTAR Medical, which will continue its development until the completion of the STAR-V clinical study. AbbVie holds an exclusive right to acquire iSTAR Medical, with potential contingent payments of up to $475M based on certain milestones.
Genmab A/S (Nasdaq: GMAB) announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) to the European Medicines Agency for epcoritamab to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in H2 2022. This follows Genmab's intention to submit a biologics license application (BLA) to the FDA for the same drug. The MAA is supported by preliminary efficacy results from the EPCORE™ NHL-1 trial, emphasizing the significant medical need for new treatment options for patients with DLBCL.
AbbVie has submitted a marketing authorization application (MAA) to the European Medicines Agency for atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist aimed at preventing migraines in adults experiencing at least four migraine days per month. This follows two pivotal Phase 3 studies indicating atogepant's efficacy; the ADVANCE trial showed significant reductions in mean monthly migraine days, while the PROGRESS study confirmed similar success for chronic migraine patients. If approved, atogepant would be the first daily oral CGRP receptor antagonist in Europe.
AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on July 29, 2022, before market opens. A live webcast of the earnings conference call will take place at 8 a.m. CT and will be accessible on AbbVie's Investor Relations website. An archived version will be available later that day. AbbVie aims to address serious health issues through innovative medicines across various therapeutic areas including immunology, oncology, and more.
AbbVie kicks off its seventh Week of Possibilities on June 27, 2022, engaging around 15,000 employees in global volunteer efforts spanning over 50 countries. This event, running from June 27 to July 1, aims to strengthen local communities through projects like renovating schools and playgrounds. Notable initiatives include creating STEM Labs and supporting Ukrainian refugees. The company's commitment to community service underscores its corporate citizenship, previously recognized as a top "Companies that Care" by Great Place to Work®.
AbbVie announced the positive opinion from the European Medicines Agency's CHMP for upadacitinib (RINVOQ) to treat adults with active non-radiographic axial spondyloarthritis (nr-axSpA). This decision is based on the successful results from the Phase 3 SELECT-AXIS 2 study, where RINVOQ met its primary endpoint of ASAS40 response at week 14 versus placebo. The European Commission's decision is anticipated in Q3 2022. Upadacitinib is currently approved for various conditions, but its use in nr-axSpA remains under review in both the EU and U.S.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.41 per share, payable on August 15, 2022, for stockholders of record by July 15, 2022. Since its inception in 2013, AbbVie has increased its dividend by over 250% and is part of the S&P Dividend Aristocrats Index, recognized for consistent annual dividend increases for over 25 years. This marks a continued commitment to returning value to shareholders while focusing on innovative therapeutic solutions.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
